

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CHLA-266

RRID:CVCL_M149

Type: Cell Line

Proper Citation

RRID:CVCL_M149

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_M149

Proper Citation: RRID:CVCL_M149

Description: Cell line CHLA-266 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Atypical teratoid/rhabdoid tumor

Defining Citation: [PMID:20922763](#), [PMID:22120608](#)

Comments: Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CHLA-266

Synonyms: CHLA266

Cross References: cancercellines:CVCL_M149, Cell_Model_Passport:SIDM01537, DepMap:ACH-001031, Wikidata:Q54812496

ID: CVCL_M149

Record Creation Time: 20220427T215459+0000

Record Last Update: 20260905T174601+0000

Ratings and Alerts

No rating or validation information has been found for CHLA-266.

No alerts have been found for CHLA-266.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Altendorf L, et al. (2026) Molecular changes during AT/RT progression associated with epithelial-mesenchymal transition and extracellular matrix changes. *Acta neuropathologica*, 152(1).

Metselaar DS, et al. (2024) Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors. *Cell reports. Medicine*, 5(9), 101700.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. *Genome biology*, 25(1), 301.

Coutinho DF, et al. (2022) Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. *Med (New York, N.Y.)*, 3(11), 774.

Parkhurst A, et al. (2022) Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. *Cell death & disease*, 13(4), 410.

Wang SZ, et al. (2019) Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 25(19), 5925.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.